Literature DB >> 22771991

Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.

Stéphanie Bianco1, Nicolas Gévry.   

Abstract

Although multiple cellular mechanisms have been proposed to explain endocrine resistance in breast cancer, the genomics events promoting the dysregulation of gene expression pattern are not clearly understood. Because chromatin plays a dynamic role in the estrogen receptor α (ERα) transcriptional program, we herein review signaling pathways implicated in endocrine resistance and try to merge them with recent epigenetic studies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22771991      PMCID： PMC3654764          DOI： 10.4161/trns.20496

Source DB:  PubMed          Journal:  Transcription        ISSN： 2154-1272


  45 in total

Review 1.  Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Authors:  Nicola Normanno; Massimo Di Maio; Ermelinda De Maio; Antonella De Luca; Andrea de Matteis; Antonio Giordano; Francesco Perrone
Journal:  Endocr Relat Cancer       Date:  2005-12       Impact factor: 5.678

Review 2.  Regulation of gene expression and cellular proliferation by histone H2A.Z.

Authors:  Amy Svotelis; Nicolas Gévry; Luc Gaudreau
Journal:  Biochem Cell Biol       Date:  2009-02       Impact factor: 3.626

Review 3.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 4.  Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.

Authors:  Jun Rao; Xiaomei Jiang; Yang Wang; Bin Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2011-08-22       Impact factor: 4.292

5.  Med1 plays a critical role in the development of tamoxifen resistance.

Authors:  Arumugam Nagalingam; Mourad Tighiouart; Lisa Ryden; Leena Joseph; Goran Landberg; Neeraj K Saxena; Dipali Sharma
Journal:  Carcinogenesis       Date:  2012-02-16       Impact factor: 4.944

6.  MicroRNA-101-mediated Akt activation and estrogen-independent growth.

Authors:  M Sachdeva; H Wu; P Ru; L Hwang; V Trieu; Y-Y Mo
Journal:  Oncogene       Date:  2010-10-18       Impact factor: 9.867

7.  AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

Authors:  Wenhui Zhao; Qingyuan Zhang; Xinmei Kang; Shi Jin; Changjie Lou
Journal:  Biochem Biophys Res Commun       Date:  2009-01-29       Impact factor: 3.575

8.  Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors:  Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal:  Nature       Date:  2008-11-12       Impact factor: 49.962

9.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

10.  Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.

Authors:  F Vesuna; A Lisok; B Kimble; J Domek; Y Kato; P van der Groep; D Artemov; J Kowalski; H Carraway; P van Diest; V Raman
Journal:  Oncogene       Date:  2011-11-07       Impact factor: 9.867
View more
  10 in total

1.  Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.

Authors:  Shiyi Yu; Xue Gong; Zhifang Ma; Meng Zhang; Ling Huang; Jun Zhang; Shuang Zhao; Tao Zhu; Zhenghong Yu; Liming Chen
Journal:  Cell Oncol (Dordr)       Date:  2019-11-07       Impact factor: 6.730

Review 2.  Role of epigenetic modifications in luminal breast cancer.

Authors:  Hany A Abdel-Hafiz; Kathryn B Horwitz
Journal:  Epigenomics       Date:  2015-02-17       Impact factor: 4.778

3.  LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression.

Authors:  S Bianco; M Jangal; D Garneau; N Gévry
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

4.  OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.

Authors:  S Bhatt; J D Stender; S Joshi; G Wu; B S Katzenellenbogen
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

5.  Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.

Authors:  María F Montenegro; María Del Mar Collado-González; María Piedad Fernández-Pérez; Manel B Hammouda; Lana Tolordava; Mariam Gamkrelidze; José Neptuno Rodríguez-López
Journal:  BMC Cancer       Date:  2014-07-26       Impact factor: 4.430

6.  Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors.

Authors:  Ciara C O'Sullivan
Journal:  Int J Cancer Clin Res       Date:  2015-10-14

7.  Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.

Authors:  Maryam Soleimani Dodaran; Simone Borgoni; Emre Sofyalı; Pernette J Verschure; Stefan Wiemann; Perry D Moerland; Antoine H C van Kampen
Journal:  BMC Cancer       Date:  2020-07-19       Impact factor: 4.430

8.  Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer.

Authors:  Maithreyi Sarma; Yara Abdou; Ajay Dhakal; Shipra Gandhi
Journal:  Breast Cancer (Auckl)       Date:  2020-12-16

9.  Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer.

Authors:  Anna Gustafsson; Elena Garre; Maria Carmen Leiva; Simona Salerno; Anders Ståhlberg; Göran Landberg
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

Review 10.  Multidrug-resistant breast cancer: current perspectives.

Authors:  Heather L Martin; Laura Smith; Darren C Tomlinson
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-01-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.